Pfizer Marks First Revenue Growth Since COVID Revenue Peak In 2022, Lifts Annual Guidance
Pfizer Marks First Revenue Growth Since COVID Revenue Peak In 2022, Lifts Annual Guidance
On Tuesday, Pfizer Inc. (NYSE:PFE) reported second-quarter adjusted EPS of $0.60, down 11% year over year, beating the consensus of $0.46.
辉瑞（Pfizer，NYSE:PFE）周二发布了第二季度调整后的每股收益报告，为0.60美元，同比下降11％，超过了0.46美元的共识预期。
The U.S. drugmaker reported sales of $13.28 billion, up 2% year-over-year (up 3% operationally), beating the consensus of $13.02 billion.
这家美国制药公司报告了132.8亿美元的销售额，同比增长2％（运营上增长3％），超过了130.2亿美元的共识预期。增长主要是由于我们的多个收购产品，主要在市场内的产品以及最近的商业推出的增长贡献，这些增长弥补了Comirnaty预期下降的影响。
The increase was primarily due to growth contributions from several of our acquired products, key in-line products, and recent commercial launches, which more than offset both an expected decline in Comirnaty.
销售额的增长主要是由于多个在市场内的产品增长的贡献、几个被收购的产品、最近商业化的推出，从而弥补了Comirnaty的预期下降。去除Comirnaty和Paxlovid的贡献后，营业收入达到了128亿美元，同比运营增长14％。
Also Read: Sangamo Stock Spikes As Pfizer Partnership Meets Goal In Late-Stage Study.
参见：Sangamo公司股价飙升，因为其与辉瑞合作的晚期研究达到目标。
Excluding contributions from Comirnaty and Paxlovid, revenues reached $12.8 billion, increased 14% operationally.
排除Comirnaty和Paxlovid的贡献，营业收入同比运营增长了14%。
In the second quarter of 2024, Comirnaty's revenues of $195 million declined by 87%. Paxlovid revenues increased 79% to $251 million.
2024年第二季度，Comirnaty的收入为19500万美元，同比下降了87％。Paxlovid的收入增长了79％，达到了25100万美元。
Vyndaqel family drugs generated sales of $2.46 billion, up 68%. Eliquis, a blood thinner drug, generated sales of $3.92 billion, up 9%.
Vyndaqel家族药物的销售额达到了24.6亿美元，同比增长68％。血液减薄机药物Eliquis的销售额达到39.2亿美元，同比增长9％。
Albert Bourla, Chairman and Chief Executive Officer, stated, "Notably, we achieved exceptional growth in our Oncology portfolio, with strong revenue contribution from our legacy-Seagen products."
主席兼首席执行官阿尔伯特·布尔拉（Albert Bourla）表示：“值得注意的是，我们的肿瘤学产品组合表现出色，其中我们旧有的Seagen产品为收入做出了强劲贡献。”
"In the second quarter, for example, we achieved year-over-year revenue growth for the first time since the fourth quarter of 2022 when our COVID revenues peaked," Bourla added.
布尔拉补充道：“例如，在第二季度，我们实现了自2022年第四季度（COVID收入达到峰值）以来的同比营收增长。”
In May, Pfizer launched a multi-year cost-cutting initiative to save approximately $1.5 billion by the end of 2027.
2024年5月，辉瑞启动了一项为期多年的削减成本行动，以在2027年底前节省大约15亿美元。
Guidance: Pfizer updates its 2024 revenue forecast to $59.5 billion—$62.5 billion, compared to prior guidance of $58.5 billion—$61.5 billion and consensus of $60.7 billion.
指引：辉瑞将其2024年营收预测更新为595亿-625亿美元，而之前的指引则为585亿-615亿美元，共识预期为607亿美元。
The company's updated guidance includes approximately $8.5 billion (vs. $8 billion expected earlier) in anticipated revenues for Comirnaty and Paxlovid, approximately $5 billion and $3.5 billion, respectively.
公司的更新指引包括：Comirnaty和Paxlovid预期收入约85亿美元（比之前预期的80亿美元多），其中分别约为50亿美元和35亿美元。
Pfizer expects 2024 operational revenue growth of 9%- 11% year over year, up from 8%- 10% provided on January 30, 2024.
辉瑞预计2024年运营收入同比增长9％-11％，高于2024年1月30日提供的8％-10％。
Pfizer expects 2024 adjusted EPS of $2.45-$2.65 compared to prior guidance of $2.15-$2.35 and consensus of $2.37.
辉瑞预计2024年调整后的每股收益为2.45美元-2.65美元，相比之前的指引2.15美元-2.35美元和共识预期2.37美元都有所增加。
Price Action: PFE stock is up 1.60% at $31.21 during the premarket session at the last check on Tuesday.
周二盘前，PFE股票最后一次检查时上涨1.60％，报31.21美元。
- With Oral Anti-Obesity Candidate Development, Pfizer Seeks Relevant And Competitive Presence – Goldman Sachs.
- 推出口服抗肥胖候选药物，辉瑞寻求相关和有竞争力的存在-高盛（Goldman Sachs）
Photo via Wikimedia Commons
照片通过Wikimedia Commons